by SH
The Luminaries in Structural Heart podcast is a program dedicated to getting to know various world personalities in cardiology. We will address issues of personal and academic history, as well as current hot topics of great relevance and keys to contemporary invasive cardiology. This podcast will be hosted by well-recognized cardiac surgeons or interventional cardiologists with extensive experience in structural heart interventions.
Language
🇺🇲
Publishing Since
4/11/2024
Email Addresses
0 available
Phone Numbers
0 available
April 18, 2025
Join hosts Dr. Dan O'Hair and Dr. Suzanne Baron in this compelling episode as they engage with esteemed guests Dr. Howard Herrmann and Dr. Michael Reardon, principal investigators of the SMART and Evolut Low Risk trials, respectively. Together, they explore the evolving landscape of structural heart interventions, analyzing groundbreaking data, clinical implications, and the future of patient care. From trial design to real-world applications, Dr. Herrmann and Dr. Reardon share firsthand insights into the science shaping tomorrow’s standards in cardiology. Whether you're a clinician, researcher, or simply passionate about cardiovascular innovation, this episode delivers invaluable perspectives straight from the frontlines of clinical discovery.
February 11, 2025
This podcast episode features our host, Dr. Kendra Grub, conversing with our guest, Dr. Ashok Seth, a renowned interventional cardiologist. Dr. Seth discusses his pioneering work introducing TAVR and other interventional technology to India and Asia over the past 30 years.Dr. Seth performed the first TAVR CoreValve self-expandable in India in 2004, marking a significant milestone in interventional cardiology. Social attitudes and a lack of reimbursement are additional barriers to TAVI adoption among the elderly in India; India has a unique patient population with more bicuspid cases and smaller annuli, which influences valve choice during procedures. Dr. Seth emphasizes tailoring valve selection to patient anatomy and lifetime management needs.The podcast also touches on the future of structural heart interventions, with Dr. Seth expressing excitement about advancements in mitral and tricuspid valve technologies.Dr. Seth advises emerging TAVI programs to focus on robust systems, standardized protocols, and a hub-and-spoke model for safe and effective outcomes.
January 29, 2025
In this episode, Dr. Roxana Mehran and Dr. Martha Gulati engage in a captivating discussion about how the SMART Trial is making a difference for women with aortic stenosis.[†,1] The SMART Trial is the largest, most rigorous clinical trial to date to randomize patients to the two most widely used TAVR devices, and to enroll predominantly women.[1] Featured faculty:Martha Gulati, MD MS FACC FAHA FASPC FESCDirector of Preventive Cardiology and Professor of Cardiology, Cedars Sinai Smidt Heart InstituteAssociate Director, Barbra Streisand Women’s Heart CenterAssociate Director, Preventive and Cardiac Rehabilitation CenterAnita Dann Friedman Endowed Chair in Women’s Cardiovascular Medicine & ResearchRoxana Mehran, MD, FACC, FESC, FAHA, MSCAIDirector, Women's Heart and Vascular Center at Mount Sinai Fuster Heart HospitalDirector, The Center for Interventional Cardiovascular Research and Clinical TrialsProfessor of Medicine (Cardiology) and Population Health Science and Policy, Icahn School of Medicine at Mount Sinai Disclosures: Faculty for this event are consultants for Medtronic and compensated for this event. Dr. Gulati: I serve on advisory boards for Novartis, Esperion, New Amsterdam and Medtronic. I serve on a DSMB for Merck. All except Medtronic unrelated to our discussion Dr. Mehran reports institutional research payments from: Abbott, Alleviant Medical, Beth Israel Deaconess Medical Center, Concept Medical, Cordis, Elixir Medical, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, Mediasphere Medical, Medtronic, Novartis, Protembis GmbH, RM Global Bioaccess Fund Management, Sanofi US Services, Inc. ; Personal fees from: Elixir Medical, IQVIA, Medtronic, Medscape/WebMD Global, NovoNordisk ; Equity <1% in: Elixir Medical, Stel, ControlRad (spouse) ; No Fees from: SCAI (Women in Innovations Committee Member), Faculty Cardiovascular Research Foundation (CRF), Women as One (Founding Director) ; Honorarium: AMA - JAMA Cardiology (Associate Editor), ACC (BOT Member, SC Member CTR Program) TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. †Evolut™ TAVR is indicated to treat patients who have been diagnosed with symptomatic severe aortic stenosis.1. Tchétché D, Mehran R, Blackman DJ, et al. Transcatheter Aortic Valve Implantation by Valve Type in Women With Small Annuli: Results From the SMART Randomized Clinical Trial. JAMA Cardiol. Published online October 9, 2024. The Medtronic CoreValve™ Evolut™ R, Evolut™ PRO+, and Evolut™ FX Systems are indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, including a cardiac surgeon, to be appropriate for the transcatheter heart valve replacement therapy. The Medtronic CoreValve Evolut R, Evolut PRO+, and Evolut FX Systems are indicated for use in patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of a surgical bioprosthetic aortic valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (e.g., STS predicted risk of operative mortality score ≥ 8% or at a ≥ 15% risk of mortality at 30 days).
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.